Eagle Wealth Advisors LLC Acquires New Shares in Amgen Inc. $AMGN

Eagle Wealth Advisors LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGN) during the first quarter, Holdings Channel reports. The institutional investor purchased 1,393 shares of the medical research company’s stock, valued at approximately $490,000.

Other large investors have also made changes to their positions in the company. Norges Bank bought a new position in Amgen during the fourth quarter worth about $2,164,162,000. Capital World Investors increased its holdings in shares of Amgen by 22.9% in the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after acquiring an additional 4,302,237 shares in the last quarter. State Street Corp increased its holdings in shares of Amgen by 4.4% in the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after acquiring an additional 1,287,310 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Amgen by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after purchasing an additional 1,035,779 shares during the period. Finally, Amundi raised its position in shares of Amgen by 41.1% during the fourth quarter. Amundi now owns 3,396,945 shares of the medical research company’s stock worth $1,111,854,000 after purchasing an additional 988,856 shares during the period. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several research analyst reports. Guggenheim decreased their price objective on Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a research report on Monday, May 4th. The Goldman Sachs Group set a $389.00 target price on shares of Amgen in a report on Friday, June 5th. Royal Bank Of Canada reaffirmed a “positive” rating on shares of Amgen in a research note on Thursday, June 18th. Canaccord Genuity Group started coverage on shares of Amgen in a report on Monday, April 20th. They issued a “hold” rating and a $366.00 price target for the company. Finally, Truist Financial increased their price objective on shares of Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a research report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Amgen has a consensus rating of “Hold” and a consensus target price of $354.42.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.85% of the stock is owned by corporate insiders.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen remains one of the most watched stocks on Zacks, and recent commentary notes the shares have had a strong multi-week and year-to-date run, suggesting continued investor interest and momentum. Article Title
• Neutral Sentiment: Viridian Therapeutics’ new FDA approval for Lumvoa is being viewed as a stronger competitor in thyroid eye disease, adding competitive pressure to Amgen’s Tepezza franchise rather than changing Amgen’s fundamentals directly. Article Title
• Negative Sentiment: The European Medicines Agency’s CHMP recommended revoking Tavneos’ marketing authorization in the EU, which raises the risk of lost international sales and creates a fresh regulatory overhang for Amgen. Article Title
• Negative Sentiment: The New England Journal of Medicine retracted the trial paper that supported Tavneos after FDA-related findings, increasing concerns about the reliability of the clinical data behind a drug that generated substantial revenue for Amgen. Article Title

Amgen Stock Performance

Shares of Amgen stock opened at $362.12 on Wednesday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The firm has a market cap of $195.44 billion, a price-to-earnings ratio of 25.20, a price-to-earnings-growth ratio of 3.62 and a beta of 0.42. The stock’s 50-day moving average is $341.06 and its 200-day moving average is $347.04. Amgen Inc. has a one year low of $269.77 and a one year high of $391.29.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same period last year, the company earned $4.90 earnings per share. Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts predict that Amgen Inc. will post 22.39 earnings per share for the current fiscal year.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.